Health

  • August 07, 2026

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen Cleary Gottlieb sue a former client it advised on the proposed sale of a holding company and the continuation of litigation between pharma giants Merck Sharp & Dohme and Merck KGaA over rights to the Merck name in the U.K.

  • August 07, 2026

    ERISA Recap: 6 Important Rulings From July

    The Ninth Circuit rejected a fund manager's bid to force a 401(k) suit into arbitration, a district court tossed a pension de-risking suit, and the D.C. Circuit unraveled a union pension fund's $13 million withdrawal liability win.

  • August 06, 2026

    7th Circ. Backs Outcome Health Execs' $1B Fraud Convictions

    The Seventh Circuit on Thursday upheld the convictions of two Outcome Health executives for lying about the company's capabilities and value in a $1 billion fraud, rejecting their argument that an overzealous pretrial freeze on millions in assets violated their constitutional right to hire the defense attorneys of their choice.

  • August 06, 2026

    GOP Sens. Vote To Hold Fauci In Contempt, AGs Open Probe

    A U.S. Senate committee voted along party lines Thursday to hold Dr. Anthony Fauci in contempt of Congress after he declined to answer questions about the government's handling of the pandemic, while the Florida, West Virginia and Louisiana attorneys general are investigating potential "self-dealing" by Fauci during the crisis.

  • August 06, 2026

    Cigna Wins Dismissal Of Pa. In-Network Pharmacy Suit

    A Pennsylvania federal judge on Thursday dismissed a suit against Cigna, Evernorth and Express Scripts from Pennsylvania pharmacy customers who alleged injury because the companies designated their community pharmacy as out-of-network, holding state-law claims were preempted by federal benefits law but allowing another chance at re-pleading.

  • August 06, 2026

    Judge Sets Feb. Trial In States' Generics Price-Fixing Suit

    A Connecticut federal judge has set a February trial date on claims from dozens of state attorneys general that generic-drug makers conspired to artificially inflate the prices of generic topical drugs.

  • August 06, 2026

    Rowan University Vet School Hit With 3 Discrimination Suits

    Rowan University's new veterinary school was hit with three separate discrimination suits in New Jersey state court from a professor, a technician and an ophthalmologist who each claim the fledgling institution retaliated against them and mishandled disability‑related concerns during the animal hospital's launch.

  • August 06, 2026

    UCHealth Accused Of Sharing Patient Data With Meta

    University of Colorado Health was hit with a proposed class action Wednesday in Colorado federal court accusing the healthcare provider of giving patients' private and legally protected health data to Meta through the use of a Facebook tracking pixel tool.

  • August 06, 2026

    Data Breach Case Against Allegheny Health Mostly Advances

    A Pennsylvania federal judge cleared most of a data breach class action against Allegheny Health System to move forward, leaving the healthcare company and its information technology vendor to face allegations that they are liable for allowing patients' sensitive information stored on internal networks to be compromised by a hacker.

  • August 06, 2026

    Goodwin, Covington Lead Braveheart Bio's $383M IPO

    Venture-backed biotechnology firm Braveheart Bio hit the public markets on Thursday after raising $383 million in its upsized initial public offering.

  • August 06, 2026

    Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push

    Tarsus Pharmaceuticals Inc. said Thursday it has agreed to acquire privately held Alkeus Pharmaceuticals Inc. for up to approximately $800 million, expanding the Irvine, California-based eye care company's pipeline into retinal disease with an experimental treatment for Stargardt disease.

  • August 06, 2026

    Shein Eyes $40B Valuation Via Hong Kong IPO, More Rumors

    Fast-fashion company Shein is seeking a $40 billion valuation through its Hong Kong initial public offering, betting platform Polymarket is eyeing a new funding round that could value it at $20 billion and Cencora's MWI Animal Health merger with Covetrus faces regulatory scrutiny.

  • August 06, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Tossed By Texas Judge

    A Texas federal court has dismissed compounding pharmacy Strive Specialties Inc.'s antitrust lawsuit against Eli Lilly and Novo Nordisk, finding it failed to allege the companies blocked competition for GLP-1 medications.

  • August 06, 2026

    Judge OKs $35M Teva Deal In Delayed Generic Inhalers Suit

    A Massachusetts federal judge has approved an antitrust settlement that will see Teva Pharmaceuticals pay $35 million to resolve claims that it schemed to delay generic competition for its QVAR asthma inhalers.

  • August 05, 2026

    Product Liability Cases To Watch: Midyear Report

    Social media companies are headed back to court over allegations that their platforms are designed to hook young people, while OpenAI faces claims that ChatGPT has meted out harmful health advice and helped users plan mass shootings. Here's what's on the radar for product liability for the rest of 2026.

  • August 05, 2026

    Drug Cos. Can't Trim Humana's Price-Fix Claims In Bellwether

    A Pennsylvania federal judge on Tuesday denied a bid by a number of generic drug manufacturers to dismiss two antitrust claims brought by health insurer Humana Inc. from an upcoming bellwether trial in long-running antitrust multidistrict litigation, finding they were brought within the statute of limitations.

  • August 05, 2026

    Kansas Judge Permanently Blocks Abortion Care Restrictions

    A Kansas state court has permanently enjoined a slew of restrictions on abortion care, including requirements that providers disclose patients' reasons for seeking an abortion to the state and inform patients about abortion pill "reversal" treatments the court said were "unlikely to be biologically plausible."

  • August 05, 2026

    Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

    Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug Amitiza should be reduced by rebates the drugmaker paid and Medicare subsidies that reduced the health plans' costs.

  • August 05, 2026

    HHS Decertifies Ky. Organ Group Amid Investigation

    After a federal investigation found that a Kentucky organ procurement organization moved forward to recover the organs of a man showing signs of life, the Department of Health and Human Services has announced it's revoking the group's certification. 

  • August 05, 2026

    Aetna, Others Hit Pharma Cos. With Xifaxan Pay-To-Delay Suit

    Health insurance companies Aetna Inc., Health Care Service Corp. and Molina Inc. have sued multiple pharmaceutical companies in Pennsylvania state court in Pittsburgh, alleging that the defendants conspired to delay the release of generic versions of the irritable bowel syndrome drug Xifaxan, in violation of antitrust laws.

  • August 05, 2026

    Mich. Parents Seek $375K In Newborn Blood Spot Case

    A group of Michigan parents has asked a federal judge to award nearly $375,000 in attorney fees and costs after they secured a consent judgment that ended part of the state's newborn blood spot retention program and required the destruction of about 3.4 million samples. 

  • August 05, 2026

    No Coverage For Assisted Living Death, Fla. Panel Says

    A Florida appellate court on Wednesday reversed a judgment that required National Assisted Living Risk Retention Group to provide coverage for a wrongful death suit from a resident's 2012 death, finding no claim was made during the relevant policy period.

  • August 05, 2026

    Fenwick-Led Attovia Therapeutics Prices Upsized $289M IPO

    Early-stage biotechnology company Attovia Therapeutics hit the public markets on Wednesday after it raised $289 million in its upsized initial public offering.

  • August 05, 2026

    Texas Firm Lands $150M HHS Services Deal For Migrant Kids

    The U.S. Department of Health and Human Services said it has entered into a $150 million contract with a small Texas law firm to provide legal services to unaccompanied immigrant children, raising concerns from former subcontractors about the firm's experience with immigration matters.

  • August 05, 2026

    Pa. Court Wipes Out $19M Verdict In Nursing Home Death Suit

    A Pennsylvania appeals court has vacated $19 million in damages, including $15 million in punitive damages, in a suit against nursing home operators and managers over the death of a resident, finding the trial court should have reconsidered damages after negating liability against two of the four defendants.

Expert Analysis

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • To Survive FCA Actions, Small Cos. Must Take Offensive Steps

    Author Photo

    A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • How US Liability Law Is Becoming The Primary Regulator Of AI

    Author Photo

    Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Methods For Challenging State Civil Investigative Demands

    Author Photo

    Ongoing challenges to enforcement actions underscore the uphill battle businesses face in arguing that a state investigation is prohibited by federal law, but when properly deployed, these arguments present a viable strategy to resist civil investigative demands issued by state attorneys general, say attorneys at Troutman Pepper.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Opinion

    SNAP Rule Confusion Risks A Compliance Crisis

    Author Photo

    Recent Supplemental Nutrition Assistance Program food restriction waivers pose a compliance crisis for legal practitioners advising food retailers, amid higher costs and lack of a coherent national standard, says Tyson-Lord Gray at Yeshiva University’s Benjamin N. Cardozo School of Law.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.